Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, with experience at Bristol Myers Squibb, Karuna Therapeutics and AbbVie. His appointment is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders, according to a press release.
Dr. Kramer's expertise aligns with Helus Pharma's mission to address unmet needs in mental health. The company is developing proprietary NSAs designed to activate serotonin pathways believed to promote neuroplasticity. Its lead candidate, HLP003, is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder.
The appointment comes as Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health. The company's pipeline includes an extensive research portfolio of investigational NSAs. Dr. Kramer's leadership in medical affairs will be crucial as Helus Pharma navigates late-stage clinical trials and prepares for potential regulatory submissions and commercialization.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit the company's website at www.helus.com. The latest news and updates are available in the company's newsroom at https://ibn.fm/HELP.
This announcement underscores Helus Pharma's commitment to advancing its pipeline of novel serotonergic agonists, which target serotonin pathways to promote neuroplasticity and could offer new treatment options for depression and anxiety. The company's lead candidate, HLP003, has shown promising data and received Breakthrough Therapy Designation, highlighting its potential to address the large unmet need in mental health.
